STOCK TITAN
  1. Home
  2. News
  3. OCX

Oncocyte Corporation - OCX STOCK NEWS

Welcome to our dedicated news page for Oncocyte Corporation (Ticker: OCX), a resource for investors and traders seeking the latest updates and insights on Oncocyte Corporation.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Oncocyte Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Oncocyte Corporation's position in the market.

News
Oncocyte Reports Full Year 2023 Financial Results
Rhea-AI Summary
Oncocyte (OCX) reported financial results for 2023, highlighted by a Bio-Rad Laboratories partnership, $15.8 million in gross proceeds from a private placement offering, and successful progress in transplant monitoring. The company achieved significant cost controls, reimbursement for VitaGraft Kidney, and commercialized GraftAssure RUO. Financially, net revenue increased by 15% for Q4 2023 and 57% for the full year 2023 compared to 2022, driven by Pharma Services revenue. However, there were increases in research and development, sales and marketing expenses, resulting in a loss from operations for both Q4 and full year 2023. Oncocyte remains optimistic about meeting critical milestones with strong investor support.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.6%
Tags
earnings
-
News
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
Rhea-AI Summary
Oncocyte (OCX) announces a private placement of common stock and pre-funded warrants, totaling 5,420,275 shares, at a purchase price of $2.9164 per share, aiming to raise capital through securities purchase agreements. The private placement is priced 'at-the-market' and is anticipated to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.6%
Tags
none
-
News
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
Rhea-AI Summary
Oncocyte (OCX) announces a partnership with Bio-Rad Laboratories (BIO) for the commercialization of GraftAssure™ assay, powered by Droplet Digital PCR. The agreement grants Bio-Rad global exclusivity in transplant monitoring commercialization, with an equity investment option upon FDA clearance. The new product is set to launch in Q2 2024 in the US and EU.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.6%
Tags
none
News
Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results
Rhea-AI Summary
Oncocyte (OCX) will release its Q4 and full-year 2023 financial results on April 12, 2024. A conference call and webcast will be held to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
earnings
-
News
Oncocyte to Present at the Sequire Investor Summit in Puerto Rico
Rhea-AI Summary
Oncocyte Corporation (OCX) CEO Josh Riggs will present a corporate overview at the Sequire Investor Summit 2024 in San Juan, Puerto Rico. The conference is scheduled for January 23-25, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
conferences
-
News
Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays
Rhea-AI Summary
Oncocyte Corporation (Nasdaq: OCX) has initiated the FDA single-site process for its VitaGraft transplant assays, positioning the company within the recent proposed rule from the FDA that seeks to oversee Lab Developed Tests (LDTs). The move is expected to create a significant competitive advantage for the company in the multi-billion-dollar transplant testing market and drive adoption beyond the current 25-30%. The company also received a positive coverage decision from MolDX for its Kidney indication, expected to launch commercially in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
none
News
Oncocyte Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Oncocyte Corporation (Nasdaq: OCX) reported positive coverage for VitaGraft Kidney, expecting commercial revenue in 1H 2024. Cash burn declined to $3.6 million, with $14.2 million in cash, equivalents, and securities as of September 30, 2023. Third quarter 2023 financial results showed a net operating loss of $6.5 million, primarily due to increased R&D expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.71%
Tags
earnings
-
News
Oncocyte to Announce Third Quarter 2023 Financial Results
Rhea-AI Summary
Oncocyte Corporation, a precision diagnostics company, will host a conference call and webcast on November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET to discuss its third quarter financial results and recent highlights. Interested parties can access the call via telephone or the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.09%
Tags
earnings
-
News
Oncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier
Rhea-AI Summary
Oncocyte's VitaGraft assay detects transplant rejection 10 months sooner than standard protocols, according to a clinical trial. Positive coverage determination received for VitaGraft Kidney. Commercialization expected in 1H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.49%
Tags
none
News
Oncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Summary
Oncocyte Corporation to participate in H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Stock OCX logo
Oncocyte Corporation

Nasdaq:OCX

OCX Rankings

#4943 Ranked by Market Cap
#5367 Ranked by Stock Gains
N/A Ranked by Dividends

OCX Stock Data

22.39M
3.73M
5.7%
55.18%
2.17%
In-Vitro Diagnostic Substance Manufacturing
Manufacturing
Link
US
Irvine

About OCX

oncocyte is focused on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics to facilitate clinical decision making in the early detection of cancer. the company's pipeline is focused on molecular tests for areas of high unmet need - lung, breast, and bladder cancers - where the current standard of diagnostic care is often ambiguous, costly, and involves invasive surgical procedures. oncocyte's diagnostics are developed based on a proprietary set of biomarkers that have been shown to differentiate benign from malignant nodules or masses. for more information, visit www.oncocyte.com.